Complimentary Webinar available: “Early Team Based Treatment For People With Psychotic Symptoms: The RAISE-Early Treatment Program Experience”
Date: Tuesday, April 14, 2015
2:00 p.m.–3:00 p.m. EST
Hear from Dr. Nina R. Schooler, Professor of Psychiatry and Behavioral Sciences at State University of New York Downstate Medical Center, as she presents “Early Team Based Treatment For People With Psychotic Symptoms: The RAISE-Early Treatment Program Experience.”
Despite high levels of marijuana use in the U.S., little is known about the effects of recreational marijuana use on daily life. In a recent study of recreational marijuana users, marijuana use was correlated with increased impulsivity on the day of use and the following day. Participants also reported higher hostility ratings – for both themselves and their perception of others – on the day they used marijuana. This effect did not last into the next day and appeared to lessen as the study progressed. Results were not impacted by other variables measured such as alcohol or nicotine use. Read the article by clicking here: http://www.drugabuse.gov/news-events/latest-science/recreational-marijuana-use-associated-increased-impulsivity-hostility-in-daily-life <http://www.drugabuse.gov/news-events/latest-science/recreational-marijuana-use-associated-increased-impulsivity-hostility-in-daily-life>
Check out this informative article written by SARDAA Board Member Dustin DeMoss on maintaining a balanced lifestyle while living with a mental illness.
A recent paper reports findings on the reduction in life expectancy among people with mental illness
A recent paper reports findings on the reduction in life expectancy among people with mental illness relative to the general population. National Institute of Mental Health (NIMH) Director Thomas Insel discusses the magnitude and reasons for this excess mortality. http://www.nimh.nih.gov/about/director/2015/mortality-and-mental-disorders.shtml <http://www.nimh.nih.gov/about/director/2015/mortality-and-mental-disorders.shtml>
Brandon Staglin went from brilliant engineering student to institutionalized. Over the next decade he fought his way back, to help found a leading brain research organization.
Click here: http://mentalhealthchannel.tv/episode/schizophrenia to view this inspirational personal and family story.
TITLE: Long-Acting Injectable Antipsychotic Medications for Schizophrenia: Changing Our Paradigms
OVERALL DESCRIPTION: Approximately 1.1% of the population worldwide has schizophrenia, a prevalence that is relatively high due to the chronic nature and early onset of this disorder. Adherence to antipsychotic medication is crucial for minimizing the symptoms of schizophrenia and maximizing the patient’s function in society. If a patient does not adhere to a medication plan, the likelihood that the patient will relapse after being stabilized symptomatically is greatly heightened. While oral medications are a tremendous help in controlling what used to be a disease that warranted permanent institutionalization, patients often struggle with full adherence with these agents for a variety of reasons. Long-acting injectable antipsychotic drugs can be integral in assisting certain patients in managing their illness, even those with first-episode schizophrenia.
JOINTLY SPONSORED BY: University of Cincinnati College of Medicine and Haymarket Medical Education (HME)
IN COLLABORATION WITH: Schizophrenia and Related Disorders Alliance of America (SARDAA)
This educational grant is supported by Otsuka America Pharmaceutical, Inc. and Janssen Pharmaceuticals
- Charles L. Raison, MD, Professor, Department of Psychiatry, College of Medicine
- Barry and Janet Lang Professor, John and Doris Norton School of Family and Consumer Sciences, Tucson, AZ
Disclaimer: The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of SARDAA.